BioInvent International AB (publ) (STO:BINV)
21.55
-0.25 (-1.15%)
Mar 23, 2026, 12:09 PM CET
BioInvent International AB Employees
BioInvent International AB had 109 employees as of December 31, 2025. The number of employees decreased by 5 or -4.39% compared to the previous year.
Employees
109
Change
-5
Growth
-4.39%
Revenue / Employee
2.08M SEK
Profits / Employee
-3.05M SEK
Market Cap
1.43B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 109 | -5 | -4.39% |
| Sep 30, 2025 | 124 | 9 | 7.83% |
| Jun 30, 2025 | 122 | 10 | 8.93% |
| Mar 31, 2025 | 118 | 9 | 8.26% |
| Dec 31, 2024 | 114 | 3 | 2.70% |
| Sep 30, 2024 | 115 | 7 | 6.48% |
| Jun 30, 2024 | 112 | 9 | 8.74% |
| Mar 31, 2024 | 109 | 7 | 6.86% |
| Dec 31, 2023 | 111 | 17 | 18.09% |
| Sep 30, 2023 | 108 | 15 | 16.13% |
| Jun 30, 2023 | 103 | 14 | 15.73% |
| Mar 31, 2023 | 102 | 16 | 18.60% |
| Dec 31, 2022 | 94 | 10 | 11.90% |
| Sep 30, 2022 | 93 | 8 | 9.41% |
| Jun 30, 2022 | 89 | 11 | 14.10% |
| Mar 31, 2022 | 86 | 12 | 16.22% |
| Dec 31, 2021 | 84 | 12 | 16.67% |
| Sep 30, 2021 | 85 | 12 | 16.44% |
| Jun 30, 2021 | 78 | 6 | 8.33% |
| Mar 31, 2021 | 74 | 5 | 7.25% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Egetis Therapeutics AB | 42 |
| Diamyd Medical AB | 41 |
| Vicore Pharma Holding AB | 37 |
| Genovis AB (publ.) | 36 |
| Saniona AB | 34 |
| Xspray Pharma AB | 26 |
| Cantargia AB | 22 |
| Medivir AB | 10 |
BioInvent International AB News
- 24 days ago - BioInvent International AB (FRA:BIX0) Q4 2025 Earnings Call Highlights: Navigating Challenges ... - GuruFocus
- 24 days ago - Q4 2025 BioInvent International AB Earnings Call Transcript - GuruFocus
- 25 days ago - BioInvent International AB: Year-End Report January 1 - December 31, 2025 - Accesswire
- 5 months ago - BioInvent International AB (FRA:BIX0) Q3 2025 Earnings Call Highlights: Strategic Focus Amidst ... - GuruFocus
- 5 months ago - Q3 2025 BioInvent International AB Earnings Call Transcript - GuruFocus
- 1 year ago - Transgene and BioInvent's Oncolytic Virus BT-001 Shows Promising Antitumor Activity in Ongoing Phase I/IIa Trial in Solid Tumors that Failed Previous Treatments - Benzinga